Inzidenz und Prävalenz von Diabetes mellitus Typ 2 in Deutschland

Wilke, Thomas; Ahrendt, P.; Schwartz, Daniel R.; Linder, Roland; Ahrens, S.; Verheyen, Frank

doi:10.1055/s-0032-1327394

Cited by 32 publications

(27 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our estimates of prevalence and upward time trend are more in line with international studies reporting higher prevalence levels in the general population. For example, Wilke et al [20] reported a standardized prevalence of 5.5% for patients with Type 2 diabetes of all ages in Germany in 2008. Additionally, we observed a significant increase in diabetes prevalence between 2006 and 2011.…”

Section: Discussionmentioning

confidence: 99%

Epidemiology and costs of diabetes mellitus in Switzerland: an analysis of health care claims data, 2006 and 2011

et al. 2014

View full text Add to dashboard Cite

BackgroundQuantifying the burden of diabetes mellitus is fundamental for managing patients in health service delivery systems and improves the understanding of the importance of prevention and early intervention of diabetes. In Switzerland, epidemiological data on diabetes are very scarce. In this study we provide a first national overview of the current situation of diabetes mellitus in Switzerland as well as the development of the prevalence, incidence, mortality and costs between 2006 and 2011.MethodsUsing health care claims data of a large health insurance group, current epidemiology and costs were determined from a sample of adult enrollees in 2011. The identification of patients with diabetes was based on prescription data of diabetes related drugs using the Anatomical Therapeutic Chemical Classification as proxy for clinical diagnosis. We further evaluated changes in epidemiology and costs between 2006 and 2011. All results were weighted with census data to achieve an extrapolation to the Swiss general population level.ResultsA total of 920’402 patients were enrolled in 2011 and 49’757 (5.4%) were identified as diabetes cases. The extrapolated overall prevalence of diabetes in Switzerland was 4.9% (2006, 3.9%). The incidence was 0.58% in 2011 (2007, 0.63%). The extrapolated mortality rate was 2.6% with no significant change over time. Annual diabetes costs to the mandatory health insurance increased from EUR 5,036 per patient in 2006 to EUR 5’331 per patient in 2011.ConclusionsThis study shows a high medical and economic burden of diabetes. The prevalence and costs of diabetes in Switzerland increased substantially over time. Findings stress the need for public health strategies to manage patients with chronic conditions and optimize resource allocation in health service delivery systems.

show abstract

Section: Discussionmentioning

confidence: 99%

Epidemiology and costs of diabetes mellitus in Switzerland: an analysis of health care claims data, 2006 and 2011

et al. 2014

View full text Add to dashboard Cite

show abstract

“…This difference, again, is explained in part by different unit prices; a second explanation for this difference, from our perspective, is the difference in applied methodologies, as discussed earlier. Given our reported number of additional healthcare costs of €3,916 per patient year, when a patient is affected by at least one UTI event, and given a German population of 80.62 million, a T2DM prevalence rate of 5.75% [23], and an estimated UTI incidence of 87 cases per 1,000 T2DM patient-years (which is based on analysis of our dataset), the UTI associated healthcare burden for the German healthcare system is more than €1.5 billion per year.…”

Section: Discussionmentioning

confidence: 99%

“…Inclusion in the T2DM-prevalent sample was confirmed via the international classification of diseases (ICD) coding if physicians documented at least one outpatient/inpatient T2DM diagnosis (i.e. ICD-10 E11.-) in 2010 [23,24,25]. …”

Section: Methodsmentioning

confidence: 99%

“…Given the increasing prevalence and burden of T2DM in all Western and developing countries and given the above-average UTI risk of diabetic patients [11,23,24,25,26,27], in part because of the aging population, there is urgent need for UTI-related healthcare burden estimates in diabetic patients. The present claims data-based analysis was conducted among German patients with T2DM to describe the real-world treatment of UTIs in this population, to investigate UTI-related healthcare resource use, to assess treatment costs associated with UTI, and to identify factors that might predict UTI-related treatment costs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Healthcare Burden and Costs Associated with Urinary Tract Infections in Type 2 Diabetes Mellitus Patients: An Analysis Based on a Large Sample of 456,586 German Patients

Wilke

Böttger

Berg

et al. 2016

Nephron

View full text Add to dashboard Cite

Objectives: We examined the real-world treatment of urinary tract infections (UTIs) in a type 2 diabetes mellitus (T2DM) population, evaluated UTI-related healthcare resource use and direct treatment costs, and assessed factors that may predict UTI-related costs. Methods: We analyzed an anonymized dataset from a regional German healthcare fund (2010-2012). UTI-associated resource use was described by the number of UTI-associated outpatient visits, the number and length of UTI-related acute hospital visits, and the number of UTI-related antibiotics prescriptions. UTI-related direct treatment costs were studied both based on these resource use numbers and, additionally, based on a comparison of all-cause annual healthcare costs of T2DM-patients who were or were not affected by a UTI. To identify factors that might predict direct treatment costs related to UTI treatment, we conducted generalized linear regression model analyses (based on gamma distribution) using sociodemographic and clinical characteristics of observed patients as available in the database as independent variables. Results: A total of 456,586 T2DM-patients were included with a mean age of 73.8, a percentage of 56.3 female patients, and a mean Charlson comorbidity index of 7.3. In our database, we observed 48,337 UTI events. The direct mean resource-based costs were €315.90 per UTI event. Older age, higher comorbidity status, at least one previous non-UTI infection, and poorer renal function were associated with higher costs, while female gender and at least one previous UTI event were associated with lower costs. In the all-cause cost analysis, healthcare costs per patient year were €3,916 higher in the UTI group than in the non-UTI group. Conclusion: Our study confirms that UTI is a common complication in patients with T2DM. Patients with T2DM who have had previous infections, who are older, and who are male, as well as patients who have more comorbidities or severe renal insufficiency, face above-average UTI treatment costs. These patient groups, therefore, should receive special attention in the real-world treatment of T2DM, which should include a regular screening of UTI risk.

show abstract

“…Die mit Typ-2-Diabetes und Übergewicht vergesellschaftete Insulinresistenz hemmt im Gefäßendothel die Produktion von Stickstoffmonoxid (NO), dem eine zentrale Rolle bei der Regulierung des Gefäßtonus zukommt [5]. [19].…”

Section: -Wochen-daten Vs Placebo ▼unclassified

Canagliflozin in der Monotherapie: Klinische Studiendaten bei Diabetes mellitus Typ 2

Matthaei

2014

Dtsch med Wochenschr

View full text Add to dashboard Cite

Inzidenz und Prävalenz von Diabetes mellitus Typ 2 in Deutschland

Abstract: T2DM is one of the most common chronic diseases in Germany. The expected demographic changes in Germany will increase the burden on the German health system caused by T2DM.

Cited by 32 publications

References 17 publications

Epidemiology and costs of diabetes mellitus in Switzerland: an analysis of health care claims data, 2006 and 2011

Epidemiology and costs of diabetes mellitus in Switzerland: an analysis of health care claims data, 2006 and 2011

Healthcare Burden and Costs Associated with Urinary Tract Infections in Type 2 Diabetes Mellitus Patients: An Analysis Based on a Large Sample of 456,586 German Patients

Canagliflozin in der Monotherapie: Klinische Studiendaten bei Diabetes mellitus Typ 2

Contact Info

Product

Resources

About